Moreover, Grade 2 complications, including symptomatic pneumonitis, could not be evaluated, though symptomatic radiation pneumonitis (Grade ≥ 2) after chemoradiotherapy was an important exclusion criterion for the administration of maintenance PD-L1 inhibitors following definitive chemoradiotherapy in the PACIFIC study [7–9]. This evidence concerns the gene CD274 and radiation pneumonitis.